EMA Authorised: Moventig (naloxegol oxalate) — Grunenthal GmbH

View source ↗

Summary

EMA authorised Moventig (naloxegol oxalate) from Grunenthal GmbH for the treatment of constipation, including opioid-induced constipation. The decision confirms…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation
• Opioid-induced Constipation
• Opioid-related Disorders

Drugs mentioned

• Moventig (naloxegol oxalate)

Snippet

Status: Authorised. Therapeutic area: Constipation;Opioid-Related Disorders. MAH: Grunenthal GmbH. Decision date: 10/04/2025